Evaluation of the Prospective Observation of erythropoietin-administration for the treatment of Acute Myocardial Infarction-II

INTERVENTION: Epoetin‐beta(12,000 unit) treatment group Epoetin‐beta (6,000 unit) treatment group Placebo treatment group CONDITION: Acute Myocardial Infarction PRIMARY OUTCOME: The improvement of left ventricular ejection fraction at the chronic phase (the mean of differences between LVEF value at 4‐7 days and that at 6 months after administration) SECONDARY OUTCOME: [Efficacy]; 1.Indexes of cardiac function 6 months after administration of epoetin‐beta, which are calculated with cardiac scintigraphy. (LVEDV, LVESV, LVEDVI, LVESVI, regional wall motion score, %uptake at resting), and defect size (%Defect Size: SRS (Summed rest Score), SDS (Summed difference Score)); 2.Survival ratio; 3.Cardiac event ratio (Cardiac death, stroke, nonlethal myocardial infarction, admission due to worsening of heart failure, revasculization, onset of heart failure symptoms); 4.NT‐ProBNP 6 months after administration. ; ; [safety] ; 1.adverse events; 2.laboratory test data; 3.vital signs (blood pressure, pulse rate) INCLUSION CRITERIA: 1) Patients with first‐time myocardial infarction 2) Patients with ST‐elevation acute myocardial infarction (AMI) who have successful reperfusion by PCI within 12 hours after the symptom onset. 3) Patients whose ejection fraction at enrollment is <50% on UCG or LVG. 4) Age: over 20 years old, under 80 years old 5) Patients who agreed with participation to the trial in writing.